Focused On-demand Library for Damage-control phosphatase ARMT1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H993

UPID:

ARMT1_HUMAN

Alternative names:

Acidic residue methyltransferase 1; Protein-glutamate O-methyltransferase; Sugar phosphate phosphatase ARMT1

Alternative UPACC:

Q9H993; Q96FC6; Q9UFY5

Background:

Damage-control phosphatase ARMT1, also known as Acidic residue methyltransferase 1, Protein-glutamate O-methyltransferase, and Sugar phosphate phosphatase ARMT1, exhibits a unique enzymatic activity. It demonstrates phosphatase activity against substrates like fructose-1-phosphate and fructose-6-phosphate, suggesting a pivotal role in hexose phosphate metabolism. Additionally, ARMT1 has O-methyltransferase activity, capable of methylating glutamate residues on target proteins, including PCNA, which implicates it in the DNA damage response.

Therapeutic significance:

Understanding the role of Damage-control phosphatase ARMT1 could open doors to potential therapeutic strategies.